BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 22, 2020
View Archived Issues
AAV-ABCB4 gene therapy causes sustained reversal of PFIC3 disease biomarkers in mice
Read More
GM1 soluble oligosaccharide shows therapeutic potential for sporadic PD in B4galnt1+/- mice
Read More
African Americans' lung tumors have unstable genomes
Read More
Young blood not all it's cracked up to be
Read More
Initiation of first-in-human study of SBT-272
Read More
FDA clears IND application for KAN-101 for the treatment of celiac disease
Read More
TMPRSS11B as a new therapeutic target in NSCLC
Read More
Results from GLP preclinical study of AAV8-hCocH gene therapy
Read More
rVSVN4CT1-EBOVGP1 Ebola virus vaccine demonstrates safety and immunogenicity in phase I study
Read More
TWIST1 as a new risk gene for coronary artery disease and stroke
Read More
Multitrait analysis predicts glaucoma susceptibility, progression
Read More
Catalent patents decorin-containing products for cancer
Read More
Yale University divulges let-7 microRNA-activating compounds for endometriosis
Read More
AlzeCure Pharma discloses new Trk-A and Trk-B modulators
Read More
DFH Therapeutics and HHS describe betulinic acid derivatives for HIV infection
Read More
Boehringer Ingelheim presents GPR142 agonists
Read More
TNFAIP1 is a tumor suppressor in heptocellular carcinoma
Read More
Tepezza approved in the U.S. for thyroid eye disease
Read More
Signs of efficacy seen with ONCOS-102 and chemotherapy in mesothelioma trial
Read More
Phase I study of TAK-169 in relapsed or refractory multiple myeloma underway
Read More
Phase I study initiated for REN-001 in McArdle disease
Read More
Anti-IL6R Mab BCD-089 begins phase III rheumatoid arthritis study
Read More